Founded in Galveston, United States, Chrysalis BioTherapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing treatments for severe respiratory disorders and acute radiation exposure. Their core mission is to address urgent unmet clinical needs, particularly focusing on conditions like acute respiratory distress syndrome (ARDS). The company's flagship product, TP508, aims to treat mild to moderate ARDS patients by reducing mortality and reversing systemic effects on vital organs such as the lungs, heart, brain, and kidneys.

Chrysalis BioTherapeutics has garnered attention from notable figures in the biotech industry and has secured investments from key stakeholders committed to advancing medical innovations. The company has achieved significant milestones in clinical trials, demonstrating the potential efficacy of TP508 in improving patient outcomes. Through its pioneering work, Chrysalis BioTherapeutics is making a substantial impact on the treatment landscape for life-threatening respiratory conditions and radiation injuries, positioning itself as a leader in the biotech sector.